{"id":"NCT01289782","sponsor":"Janssen R&D Ireland","briefTitle":"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients","officialTitle":"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 vs Placebo as Part of a Treatment Regimen Including Peginterferon α-2a and Ribavirin in Treatment-naïve, Genotype 1 Hepatitis Cinfected Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02","primaryCompletion":"2013-01","completion":"2013-01","firstPosted":"2011-02-04","resultsPosted":"2014-06-04","lastUpdate":"2014-06-04"},"enrollment":395,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"TMC435","otherNames":[]},{"type":"DRUG","name":"Peginterferon alpha-2a (PegIFN alpha-2a)","otherNames":["Pegasys"]},{"type":"DRUG","name":"Ribavirin (RBV)","otherNames":["Copegus"]}],"arms":[{"label":"TMC435","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to investigate the effectiveness and safety of TMC435 compared with placebo in participants who are infected with genotype 1 hepatitis C virus who have never received treatment before. Participants will also receive peginterferon alpha-2a and ribavirin as part of their treatment.","primaryOutcome":{"measure":"The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)","timeFrame":"Week 36 or Week 60","effectByArm":[{"arm":"TMC435 150mg 12Wks PR24/48","deltaMin":79.5,"sd":null},{"arm":"PBO 12Wks PR48","deltaMin":50,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":62,"countries":["United States","Australia","Canada","Germany","Mexico","New Zealand","Puerto Rico","Romania","Russia","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["25445400","24907225"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":264},"commonTop":["Fatigue","Headache","Nausea","Rash","Influenza like illness"]}}